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Primary Tumour Size and Metastasis in Thyroid Cancers

RESEARCH COMMUNICATION
Threshold Primary Tumour Sizes for Nodal and Distant
Metastases in Papillary and Follicular Thyroid Cancers
Maseeh uz Zaman1, Nosheen Fatima2, Zafar Sajjad1, Jaweed Akhtar1, Najmul
Islam1, Qamar Masood1, Asma Ahmed1
Abstract
Background: In papillary and follicular thyroid cancers (PTC, FTC), nodal and distant metastasis are
generally considered important determinants of recurrence and survival, respectively. However, there is no
consensus about the threshold primary tumour size (PTS) for these determinants. The aim of this study was to
assess size relationships for developing nodal, pulmonary, bone and overall distant metastases. Methods: This
prospective study covered 139 (93 females and 46 males) consecutive biopsy proven patients with PTC (114/139,
mean age 41.0 ±15.7 years, M: F, 35%:65%) and FTC (25/139, mean age 39.2 ± 14.3 years, M: F: 24%:76%).
Results: Average primary tumor size was 23.4 ± 11.1 mm and 26.5 ± 13.1 mm for PTC and FTC respectively
(p value=0.223). Nodal metastasis was found more common in PTC than FTC (49% vs 28%, p value <0.05),
whereas overall distant metastasis was approximately the same (13% and 24%, p value =0.277); however, bone
metastasis was significantly higher in FTC than PTC (24% vs 5%, p value <0.05). Cumulative risk for nodal
and distant metastases for FTC and PTC starts at PTS <20 mm and may indicate an unusual aggressive tumor
behavior in the studied population. Highest cumulative risk for nodal and pulmonary metastases in PTC and
for bone metastasis in FTC was found to be ≥50 mm PTS. Conclusion: We conclude that a PTS of <20 mm may
indicate an unusual aggressive tumor behavior with highest cumulative risk for nodal and pulmonary metastases
in PTC and for bone metastasis in FTC with a cutoff of ≥50 mm.
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Introduction

Materials and Methods

Well differentiated thyroid cancer (WDTC) which
includes papillary (PTC) and follicular thyroid cancers
(FTC) is an uncommon malignancy with a reported
worldwide incidence of 0.5-10/100,000 population
(Franceschi and Vecchia, 1994). These tumors have an
indolent clinical course with late relapse. The outcome
of patients with WDTC has been determined by multiple
factors. It has been reported that higher recurrence is
closely linked to lymph node metastasis (Coburn and
Wanebo, 1992). Increasing primary tumor size (PTS) has
been found to have correlation with an increased risk of
extrathyroidal growth and distant metastasis (Machens et
al., 2005). However, the single most important determinant
of survival in this condition is distant metastasis [worse
with bone metastasis] (DeGroot et al., 1990) with the
median survival of 4.1 years (Shoup et al., 2003). A PTS
of > 2 cm has been considered as a threshold for distant
metastasis and as a demarcation between T1 and T2 lesions
by American Thyroid Association (ATA) in its recent
guidelines (Cooper et al., 2009).
The aim of this study was to find out threshold primary
tumour sizes for developing nodal, pulmonary, bone and
over all distant metastasis.

This is a prospective study which included 139 (93
females and 46 males) consecutive biopsy proven patients
with WDTC who attended nuclear medicine section of
Karachi Institute of Radiotherapy and Nuclear Medicine
(KIRAN), Karachi, Pakistan for radioiodine-131 (131I)
treatment from January 2005 till July 2011. These patients
were referred from The Aga Khan University Hospital
(AKUH), Karachi, Pakistan. The study was duly approved
by the ethical committee of the Institute. We included
only those patients who had complete information of PTS
as mentioned in their histopathology reports, ultrasound
neck, serum TSH >30 IU/ml, stimulated thyroglobulin
level with antibodies, 131I ablation and a post therapy
whole body iodine scan (WBIS). Patients with no
information about tumor size in histopathology reports
and histopathology other than PTC, follicular variant of
PTC and FTC (like Hurtle cell, tall, columnar, sclerosing
or insular type or well differentiated tumor of unknown
malignant potential ) were excluded.  For confirmation of
nodal metastasis histopathology was used as gold standard
while 131I avid distant metastases (lung, bone or soft tissue)
seen on WBIS were confirmed by imaging modalities like
ultrasound, CT and MRI.
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Table 1. Patients’ Demographics
Papillary Thyroid Follicular Thyroid p value
Carcinoma (PTC) Carcinoma (FTC)
(114)
(25)		

Age (mean± SD) years
40.96 ± 15.7 39.16 ±14.29
Male
40 (35%)
06 (24%)
Female
74 (65%)
19 (76%)
Primary Tumor Size			
Mean ± SD in mm
23.4 ± 11.1 26.5 ± 13.1
Post-op Thyroglobulin			
Median (range) ng/dl
14 (0.15-12000) 77 (3.5-6900)
Pot-op TSH			
Median (range) IU/L
60 (2.25-100)
50 (5-100)
Nodal Metastases
56 (49%)
7 (28%)
Distant Metastases			
Overall
15 (13%)
6 (24%)
Bone
06 (5%)
6 (24%)
Pulmonary
10 (9%)
2 (8%)

0.588
0.409
0.223
0.194
0.138
0.046*
0.277
0.006*
0.818

Figure 2. Cumulative Frequency Risk for Overall
Distant Metastases with Relation to Primary Tumor
Dize of Papillary and Follicular Thyroid Cancers

SD, Standard Deviation; TSH, Thyroid Stimulating Hormones;
*p<0.05 (statistically significant)

Figure 3. Cumulative Frequency Risk for Bone
Metastasis with Relation to Primary Tumor Size of
Papillary and Follicular Thyroid Cancers
Figure 1. Cumulative Frequency Risk for Nodal
Metastasis with Relation to Primary Tumor Size of
Papillary and Follicular Thyroid Cancers
Statistical Analysis
Categorical and continuous data were tested on
univariate analysis using the two-tailed Chi Square test.
For comparative analysis of cumulative risks between both
tumor entities, the Kaplan–Meier method (log-rank test)
was used. The level of significance was set at P< 0.05.
Commercial statistical software packages (SPSS version
12 and MedCalc®) were used.

Results
We included biopsy proven 114/139 (82%) patients
(mean age 40.96 ±15.7 years, M: F, 35%:65%) of PTC and
25/139 (18%) cases (mean age 39.16 ± 14.29 years, M: F:
24%:76%) of FTC. Out of these 139 patients, 103 had total
thyroidectomy, 36 had completion thyroidectomy and in
63 patients nodal dissection was also performed (Table 1).
Average primary tumor size was 23.4 ± 11.1 mm and 26.5
± 13.1 mm for PTC and FTC respectively (p value=0.223).
Nodal metastasis was found more common in PTC than
FTC (49% Vs 28%, p value <0.05). Cumulative frequency
risk for nodal metastasis in PTC rises linearly with PTS
(starting at a PTS of 8-10 mm) (Figure 1). For FTC,
cumulative frequency risk for nodal metastasis increases
with a PTS between 12-25 mm followed by a plateau up
to 50 mm and then an exponential rise is seen after > 50
mm PTS (p value <0.05; Log rank).  Incidence of overall
distant metastasis was same for PTC and FTC (13% and
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Figure 4. Cumulative Frequency Risk for Pulmonary
Metastasis with Relation to Primary Tumor Size of
Papillary and Follicular Thyroid Cancers
24%, p value=0.277, Table 1) with a congruent cumulative
frequency risk for PTS in FTC and PTC (p value =
0.844; log rank, Figure 2) however, bony metastasis was
significantly higher in FTC than PTC (24% Vs 5%, p value
<0.05, Table 1). For FTC cumulative frequency risk for
bony metastasis was started at PTS of 12 mm or more in
a linear trend up to 25 mm followed by constant response
between 25-50 mm when an exponential rise was noted
at 50mm (p value <0.05; Log rank, Figure 3). For PTC,
the cumulative risk for bone metastasis shows progressive
rise for a PTS of 15-25 mm then followed by plateau in
rest of its course. Similarly, the incidence of pulmonary
metastasis was same (p value=0.818, Table 1). In PTC
the cumulative frequency risk for pulmonary metastasis
showed an initial linear relation at PTS 20-25 mm then
a constant response between 25-38 mm followed by an
exponential ascend. In FTC the cumulative frequency
risk for pulmonary metastasis was observed at PTS of 12
mm with a slight rise till 25 mm and then it followed a
constant response (p value = 0.59; Log rank, Figure 4).

DOI:http://dx.doi.org/10.7314/APJCP.2012.13.6.2473
Primary Tumour Size and Metastasis in Thyroid Cancers

Discussion
According to various reports patients with FTC are
on average 3-6 years older and have larger PTS than PTC
(Mazaferri and Jhiang 1994; Hölzer et al., 1996; Hundahl
et al., 1996). A delay in diagnosis due to inability of fine
needle aspiration (FNA) to delineate between adenoma
and carcinoma (Cerutti et al., 2004) is supposed to be
one of the major factors. However, in this study PTS and
mean age of patients with FTC and PTC were marginally
different (non-significant p values). The most plausible
explanation for this fact might be an early referral and
proactive approach employed in patients with thyroid
nodule resulted in early diagnosis of follicular neoplasm.
Cumulative risk for nodal metastasis for PTC was
higher than FTC due to early and predominant nodal
spread of PTC as indicated by steeper curve for PTC.
However, position of anchoring points on the ordinate (x
intercept) of the curves showed a threshold PTS of 8-10
mm for PTC and 12-14 mm for FTC. This is an important
finding in this study as thyroid nodules <20mm size are
considered low risk and TNM classification has used 20
mm demarcation between T1 and T2 lesions (Sobin and
Wittekind, 2002). Exponential rise in nodal metastasis in
FTC after 50mm PTS may be explained by higher degree
of invasion associated with larger tumor size (Asari et
al., 2009). Incidence of nodal metastasis in PTC in this
study is 56% which coincides with reported incidence
of 23-56% (Grebe and Hay, 1996; Shaha, 1998) but
incidence of nodal metastasis in FTC in our study (28%)
is higher than the reported incidence of 5-13% (Soh and
Clark, 1996). Higher incidence of nodal metastasis in
FTC and at a PTS <20 mm (both FTC and PTC) in this
study indicate a possible aggressive behavior of disease
in studied population which needs further studies for
precise evaluation.
In our study the incidence of distant metastasis overall
was statistically not significant between PTC and FTC
and this is in contrary to most of the published studies
which show higher incidence in FTC (Shaha et al., 1997).
This fact may be explained by small sample size of FTC
cohort. Another possible explanation might be an unusual
aggressive nature thyroid cancer in our region as depicted
by an appreciable number of nodal metastasis with small
PTS and congruent cumulative risk for distant metastasis
overall with respect to PTS. Higher incidence of bone
metastasis in FTC with a linear cumulative frequency risk
with respect to PTS is explained by hematogenous spread
of tumor (Schlumberger, 1998) and this correlates well with
the reported incidence (Durante et al., 2006). However,
there are reports which found no difference between PTC
and FTC for cumulative risks of distant metastasis to
the bone (Machens and Wanebo, 2005). The cumulative
frequency risk of PTC shows a relatively persistent and
low risk for bony metastasis for increasing PTS and this
could be explained by well known predominant nodal
route of dissemination of PTC. However, FTCs show an
exponential rise in risk of bone metastasis for PTS >50
mm (approaching almost 100%) which denotes threshold
PTS > 50 mm as an important predictor of bone metastasis
in FTC. The incidence of pulmonary metastasis in FTC

and PTC are statistically similar (non significant p value)
and this is concurred with published data (Machens and
Wanebo, 2005). The cumulative frequency risk of FTC
for pulmonary metastasis shows a low but appreciable
risk even for tumor size between 10-20 mm which draws
attention towards a possible aggressive tumor nature in
studied population. The cumulative risk of pulmonary
metastasis for PTC shows a progressive increase and an
exponential rise (>60%) for a PTS >50 mm (threshold
size to predict pulmonary metastasis for PTC). We don’t
have any plausible explanation for predilection of PTC
for pulmonary metastasis and FTC for bone metastasis
for a threshold PTS of 50 mm and needs more studies to
probe this aspect of pathogenesis.
We conclude that (1) Cumulative risk for nodal and
extra-nodal metastases for FTC and PTC starts at PTS
<20 mm and may indicate an unusual aggressive tumor
behavior in studied population; (2) highest cumulative
risk for nodal and pulmonary metastases in PTC and for
bone metastasis in FTC was found to be ≥50 mm PTS.
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